Source:http://linkedlifedata.com/resource/pubmed/id/11589425
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
2001-10-8
|
pubmed:abstractText |
Braak's neurofibrillary tangle (NFT) pathology staging system of Alzheimer disease (AD) correlates generally with clinical data. Recently, Braak's group proposed an Abeta-protein staging based on the progression of amyloid deposition in the medial temporal lobe. To examine its clinical validity and evaluate whether it adds predictive power to NFT-based staging, we performed a study comparing both neuropathological classifications with clinical dementia rating scale (CDR) scores in a large autopsy series. The 2 neuropathological staging systems were strongly correlated. Their association with clinical severity was highly significant. However, the strength of the relationship was greater for NFT-based staging. It accounted for 26.5% of the variability in clinical severity, Abeta-protein-based staging for 13.0%, and age for 4.4%. Compared to NFT-based staging, the Abeta-protein-based system was less able to distinguish mild cognitive changes from dementia and showed marked overlap among the various stages of cognitive decline. In a multivariate model, NFT and age together accounted for 27.2% of the clinical variability and the addition of Abeta-protein deposition staging could only explain an extra 2.9%. Our data support the close relationship between NFT progression and amyloid formation within the medial temporal lobe proposed by Braak's group but demonstrate the limited value of Abeta-protein deposition staging in terms of clinicopathological correlations.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0022-3069
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
60
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
946-52
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:11589425-Aged,
pubmed-meshheading:11589425-Aged, 80 and over,
pubmed-meshheading:11589425-Aging,
pubmed-meshheading:11589425-Alzheimer Disease,
pubmed-meshheading:11589425-Amyloid beta-Peptides,
pubmed-meshheading:11589425-Brain,
pubmed-meshheading:11589425-Cognition Disorders,
pubmed-meshheading:11589425-Female,
pubmed-meshheading:11589425-Humans,
pubmed-meshheading:11589425-Logistic Models,
pubmed-meshheading:11589425-Male,
pubmed-meshheading:11589425-Middle Aged,
pubmed-meshheading:11589425-Multivariate Analysis,
pubmed-meshheading:11589425-Neurofibrillary Tangles,
pubmed-meshheading:11589425-Statistics, Nonparametric
|
pubmed:year |
2001
|
pubmed:articleTitle |
Clinical validity of A beta-protein deposition staging in brain aging and Alzheimer disease.
|
pubmed:affiliation |
Department of Psychiatry, HUG Belle-Idée, University of Geneva School of Medicine, Switzerland.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Validation Studies
|